ATE363275T1 - Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus) - Google Patents

Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)

Info

Publication number
ATE363275T1
ATE363275T1 AT99917179T AT99917179T ATE363275T1 AT E363275 T1 ATE363275 T1 AT E363275T1 AT 99917179 T AT99917179 T AT 99917179T AT 99917179 T AT99917179 T AT 99917179T AT E363275 T1 ATE363275 T1 AT E363275T1
Authority
AT
Austria
Prior art keywords
tacrolimus
formulation containing
gel formulation
pharmaceutical gel
tricyclic
Prior art date
Application number
AT99917179T
Other languages
English (en)
Inventor
Rinta Ibuki
Fumio Shimojo
Satoshi Ueda
Toshihiko Toyoda
Masayuki Yamanaka
Erika Yoshida
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE363275T1 publication Critical patent/ATE363275T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99917179T 1998-04-27 1999-04-26 Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus) ATE363275T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11727198 1998-04-27

Publications (1)

Publication Number Publication Date
ATE363275T1 true ATE363275T1 (de) 2007-06-15

Family

ID=14707636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99917179T ATE363275T1 (de) 1998-04-27 1999-04-26 Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)

Country Status (24)

Country Link
US (2) US6673808B1 (de)
EP (1) EP1074255B1 (de)
JP (1) JP3732525B2 (de)
KR (1) KR100406823B1 (de)
CN (1) CN1161117C (de)
AR (1) AR018330A1 (de)
AT (1) ATE363275T1 (de)
AU (1) AU749475B2 (de)
BR (1) BR9910336A (de)
CA (1) CA2326222C (de)
DE (1) DE69936195T2 (de)
ES (1) ES2284248T3 (de)
HK (1) HK1038884B (de)
HU (1) HUP0104452A3 (de)
ID (1) ID29262A (de)
IL (1) IL139210A (de)
NO (1) NO20005399L (de)
NZ (1) NZ507345A (de)
PL (1) PL343627A1 (de)
RU (1) RU2203058C2 (de)
TR (1) TR200003108T2 (de)
TW (1) TW565461B (de)
WO (1) WO1999055332A1 (de)
ZA (1) ZA200005378B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
WO2000066122A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
MX368013B (es) * 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4579920B2 (ja) * 2004-06-24 2010-11-10 興和株式会社 アトルバスタチン外用剤組成物
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
PL1872783T3 (pl) * 2005-04-21 2012-05-31 Santen Pharmaceutical Co Ltd Środek leczniczy w schorzeniach rogówkowo-spojówkowych
EP1904056B1 (de) 2005-07-18 2009-04-29 Minu, L.L.C. Verwendung von Makroliden zur Wiederherstellung der Kornealempfindungen
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
WO2010041684A1 (ja) 2008-10-08 2010-04-15 高田製薬株式会社 タクロリムス外用剤
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
JP2011102260A (ja) * 2009-11-11 2011-05-26 Takada Seiyaku Kk タクロリムス外用剤
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CA2825786A1 (en) * 2011-01-31 2012-08-09 Osaka University Externally-used drug for treating skin disorder and method for producing same
WO2021149827A1 (ja) * 2020-01-24 2021-07-29 ノーベルファーマ株式会社 ラパマイシン含有外用剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454113A (en) * 1982-09-21 1984-06-12 Scm Corporation Stabilization of oil and water emulsions using polyglycerol esters of fatty acids
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
DK175235B1 (da) * 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
EP0594600A1 (de) * 1990-03-13 1994-05-04 FISONS plc Immunosuppressive makrozyklische verbindungen
JPH05507915A (ja) * 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのfk506等のマクロライド化合物の用途
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
EP0480623A1 (de) * 1990-10-11 1992-04-15 Merck & Co. Inc. Halomakrolide und Derivate mit immunosuppressiver Wirkung
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
TW213418B (de) * 1991-05-02 1993-09-21 Kuko Seiyaku Kk
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
JPH06128148A (ja) * 1992-04-30 1994-05-10 Dotsuto:Kk 皮膚外用剤
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
JP2523428B2 (ja) * 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
CN100335063C (zh) * 1994-10-26 2007-09-05 诺瓦蒂斯有限公司 药物组合物
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
CZ283516B6 (cs) 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
EP0978288A4 (de) * 1997-04-11 2006-07-12 Astellas Pharma Inc Medizinische zusammensetzung

Also Published As

Publication number Publication date
AR018330A1 (es) 2001-11-14
CA2326222A1 (en) 1999-11-04
TW565461B (en) 2003-12-11
US6586444B2 (en) 2003-07-01
WO1999055332A8 (en) 2000-02-17
NO20005399D0 (no) 2000-10-26
ID29262A (id) 2001-08-16
US6673808B1 (en) 2004-01-06
DE69936195T2 (de) 2007-09-13
US20020061907A1 (en) 2002-05-23
CN1307475A (zh) 2001-08-08
KR100406823B1 (ko) 2003-11-21
BR9910336A (pt) 2001-09-25
IL139210A0 (en) 2001-11-25
TR200003108T2 (tr) 2001-02-21
ES2284248T3 (es) 2007-11-01
DE69936195D1 (de) 2007-07-12
NO20005399L (no) 2000-10-26
NZ507345A (en) 2002-12-20
RU2203058C2 (ru) 2003-04-27
KR20010042589A (ko) 2001-05-25
EP1074255A1 (de) 2001-02-07
EP1074255B1 (de) 2007-05-30
IL139210A (en) 2005-11-20
EP1074255A4 (de) 2002-02-13
ZA200005378B (en) 2002-08-23
CA2326222C (en) 2008-09-23
JP3732525B2 (ja) 2006-01-05
AU749475B2 (en) 2002-06-27
HUP0104452A3 (en) 2004-05-28
HK1038884A1 (en) 2002-04-04
CN1161117C (zh) 2004-08-11
PL343627A1 (en) 2001-08-27
WO1999055332A1 (en) 1999-11-04
HK1038884B (zh) 2005-05-06
AU3537299A (en) 1999-11-16
HUP0104452A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
DE69936195D1 (de) Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
DE69525148D1 (de) Pharmazeutische formulierung
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
ATE228823T1 (de) Pharmazeutische aerosolformulierung
DE69940904D1 (de) Pharmazeutische zusammensetzung enthaltend epothilone
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
ID24654A (id) Formulasi farmasi omeprazola
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
NO953874D0 (no) Farmasöytisk preparat inneholdende lipofile legemidler
HUP0004534A3 (en) Pharmaceutical formulation containing olanzapine
DE69831620D1 (de) Arzneizubereitungen enthaltend Kannabinoide
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DE59711477D1 (de) Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
NO996372L (no) Fast farmasøytisk preparat inneholdende benzofuanderivater
DE59915033D1 (de) Pharmazeutische Zubereitung
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ID30032A (id) Formulasi farmasi
DE69708130D1 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
ATE260094T1 (de) Mikronisierte bicyclische arzneistoffe enthaltende pharmazeutische zusammensetzungen
AR025867A1 (es) Formulacion portasdora farmaceutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties